XOMA Corporation is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
XOMA's scientific research produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. Two of the assets were developed through the XOMA Metabolic or XMet platform, which consists of separate classes of Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of metabolic disorders.
XOMA 358, XOMA's lead product candidate, is a is a fully human negative allosteric antibody that reduces insulin receptor activity. XOMA recently initiated a Phase 2 proof-of-concept (POC) study in patients with congenital hyperinsulinism (CHI) and initiated a Phase 2 POC study in another rare hyperinsulinemic hypoglycemic (low blood glucose caused by excessive insulin produced endogenously) indication, post-bariatric surgery (PBS) induced hyperinsulinism.
XOMA 129, a novel antibody fragment (Fab) from the XMetD program, designed as a potential treatment for severe acute hypoglycemia. Preclinical data was presented at the Endocrine Society Meeting (ENDO 2016) in April.
XOMA is located in Berkeley, California.
Dec 21, 2016
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update
Nov 9, 2016
XOMA Reports Third Quarter 2016 Achievements and Financial Results
View all »Events & Presentations
Sep 15, 2016 at 4:30 PM ET
XOMA 358 Clinical Update Webcast